The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.
Amylyx Pharmaceuticals, the maker of Relyvrio, the newest treatment approved for amyotrophic lateral sclerosis (ALS), announced on Thursday that it would withdraw the drug from the market due to negative clinical trial results, according to the New York Times. Last month, the company announced that the results of a 48-week trial of 664 patients showed that the treatment did not work better than a placebo. Consequently, Amylyx Pharmaceuticals began the process of withdrawing the drug in both the US and Canada. As of Thursday, no new patients will be able to start the drug, while current patients who want to continue it can be transitioned to a free drug program. When the FDA approved Relyvrio in September 2022, there was not yet sufficient evidence that it could help slow disease progression or help patients live longer; it decided to green light the medication anyway, citing data showing the treatment to be safe and the desperation of patients with ALS.
Jerome Adams, former President Trump’s surgeon general, is advocating for conservative states to support needle exchanges as a strategy to reduce infectious disease transmissions and save lives during the fentanyl epidemic, according to Axios. In an opinion piece he co-authored, Adams argued that making illicit drug use easier has been shown to improve public health and reduce societal costs; needle exchanges provide users with clean syringes to cut the odds of disease transmission from shared needles. He added that the programs also provide overdose prevention education and tools, community support services, and treatment and recovery options. Adams’s support of the programs comes as officials in some conservative states have moved to cut them as they feel the programs send the wrong message, threaten public safety, and are not effective.
Federal health officials announced Wednesday that new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases, according to the Associated Press. Data released by the CDC for 2022 show 4848 new infections, down from 5023 reported the year before; the new infection rate dropped 6%. This comes after cases consistently increased since 2013 due to drug users injecting heroin and fentanyl during the opioid epidemic. Experts explained that successful prevention efforts and needle exchanges could have contributed to the 6% decline. They also noted that they are unsure whether this decline is the start of a downward trend or a statistical blip; seeing the 2023 and 2024 data when available will help public health officials better understand the situation. While infection rates declined for White Americans, they continued to rise in Black, Latino, and Native American communities.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use
April 27th 2024Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More